Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
59,244,054
-
Total 13F shares
-
36,858,851
-
Share change
-
+2,306,702
-
Total reported value
-
$375,589,972
-
Put/Call ratio
-
90%
-
Price per share
-
$10.19
-
Number of holders
-
110
-
Value change
-
+$26,958,804
-
Number of buys
-
66
-
Number of sells
-
37
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q4 2023
As of 31 Dec 2023,
Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) was held by
110 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,858,851 shares.
The largest 10 holders included
MPM BioImpact LLC, Blue Owl Capital Holdings LP, FRANKLIN RESOURCES INC, BVF INC/IL, BlackRock Inc., VANGUARD GROUP INC, BRAIDWELL LP, AMERICAN INTERNATIONAL GROUP, INC., Nextech Invest Ltd., and CITADEL ADVISORS LLC.
This page lists
110
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.